Pacific Biosciences of California, Inc. (PACB) Stock
Key stats
- Market cap
- $652.57M
- Price / Earnings ratio
- -5.3x
- EPS (TTM)
- -$0.42
- Volume
- Loading
- 52-week high
- $3.44
- 52-week low
- $1.07
Source: third-party data provider, as of November 13, 2026
Compare with PACB
Recent news

Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3
Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3
PACB

Pacific Biosciences of California (PACB) Rises As Market Takes a Dip: Key Facts
Pacific Biosciences of California (PACB) Rises As Market Takes a Dip: Key Facts
PACB

Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
PACB

Cathie Wood-Led Ark Invest Sells PLTR, GOOG, SHOP Stocks — But Loads Up On PACB, FRNM And Other Biotech Firms
Cathie Wood-Led Ark Invest Sells PLTR, GOOG, SHOP Stocks — But Loads Up On PACB, FRNM And Other Biotech Firms
PACB
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 46.07
- MACD 12/26/9
- 0.08
- EMA 9 of MACD
- 0.13
- MACD histogram
- -0.06
- SMA 50
- $1.98
- Price above SMA 50
- EMA 50
- $2.06
- Price above EMA 50
- SMA 200
- $1.61
- Price above SMA 200
- EMA 200
- $1.79
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.11 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3
Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3
PACB

Pacific Biosciences of California (PACB) Rises As Market Takes a Dip: Key Facts
Pacific Biosciences of California (PACB) Rises As Market Takes a Dip: Key Facts
PACB

Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
PACB

Cathie Wood-Led Ark Invest Sells PLTR, GOOG, SHOP Stocks — But Loads Up On PACB, FRNM And Other Biotech Firms
Cathie Wood-Led Ark Invest Sells PLTR, GOOG, SHOP Stocks — But Loads Up On PACB, FRNM And Other Biotech Firms
PACB

Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
PACB

Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
PACB

PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics
PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics
PACB

Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today
PACB

PacBio Deepens AI Drug-Discovery Push With TychoBio Deal — PACB Stock Takes A Breather After 103% Rally
PacBio Deepens AI Drug-Discovery Push With TychoBio Deal — PACB Stock Takes A Breather After 103% Rally
PACB

Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts
PACB
News tone: automated (AI) classification of the article's content, not a price prediction.
About Pacific Biosciences of California, Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Mark Van Oene Ph.D. | CEO, President & Director | 1973 |
| Mr. James R. Gibson II | CFO & Principal Accounting Officer | 1970 |
| Mr. Christian O. Henry M.B.A. | Senior Business Advisor & Director | 1968 |
| Dr. Stephen Turner Ph.D. | Co-Founder | 1968 |
| Dr. Brett Atkins J.D., Ph.D. | General Counsel & Corporate Secretary | — |
| Ms. Natalie Welch | Chief People Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 46.07
- MACD 12/26/9
- 0.08
- EMA 9 of MACD
- 0.13
- MACD histogram
- -0.06
- SMA 50
- $1.98
- Price above SMA 50
- EMA 50
- $2.06
- Price above EMA 50
- SMA 200
- $1.61
- Price above SMA 200
- EMA 200
- $1.79
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $2.00
- Average
- $2.57
- High
- $3.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -13.1 | -3.2 | ||||||||||
| 2022 | -46.5 | +4.2 | -25.2 | -33.1 | -17.8 | -13.8 | -2.2 | +31.1 | -1.4 | +44.8 | +22.0 | -26.2 |
| 2023 | +39.7 | -20.9 | +32.0 | -8.9 | +9.5 | +3.4 | +2.5 | -15.4 | -26.8 | -23.2 | +42.0 | +10.5 |
| 2024 | -32.1 | -18.2 | -27.7 | -54.8 | +5.9 | -26.7 | +71.7 | -28.6 | +26.9 | +34.0 | -21.7 | -5.2 |
| 2025 | -14.4 | -0.7 | -10.6 | -1.8 | -13.5 | +25.3 | +7.0 | -1.5 | +0.0 | +69.6 | +3.6 | -16.1 |
| 2026 | +22.8 | -18.4 | -18.5 | +17.8 | -6.9 | +6.3 | -19.5 | -4.2 | +85.2 | +4.0 | -11.1 |



